Nonviral delivery of synthetic siRNAs in vivo.
Sequence-specific gene silencing using small interfering RNA (siRNA) is a Nobel prize-winning technology that is now being evaluated in clinical trials as a potentially novel therapeutic strategy. This article provides an overview of the major pharmaceutical challenges facing siRNA therapeutics, focusing on the delivery strategies for synthetic siRNA duplexes in vivo, as this remains one of the most important issues to be resolved. This article also highlights the importance of understanding the genocompatibility/toxicogenomics of siRNA delivery reagents in terms of their impact on gene-silencing activity and specificity. Collectively, this information is essential for the selection of optimally acting siRNA delivery system combinations for the many proposed applications of RNA interference.
SA Pharma, Sutton Coldfield, West Midlands, United Kingdom. SA_Pharma@hotmail.co.uk
Saghir
S
Akhtar
Ibrahim F
IF
Benter
D000818:Animals; D016503:Drug Delivery Systems; D006801:Humans; D034622:RNA Interference / Q000187:drug effects*; D034741:RNA, Small Interfering / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D043922:Toxicogenetics; D014780:Viruses
D034741:RNA, Small Interfering